top of page
ATractiB
FIRST-LINE ATEZOLIZUMAB WITH PACLITAXEL AND BEVACIZUMAB FOR ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER
CLINICAL TRIAL DETAILS
THE ATRACTIB TRIAL IS A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY EVALUATING THE COMBINATION OF ATEZOLIZUMAB, PACLITAXEL AND BEVACIZUMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER (aTNBC), INDEPENDENTLY OF PD-L1 STATUS. THE PRIMARY ENDPOINT WAS INVESTIGATOR-ASSESSED PROGRESSION-FREE SURVIVAL (PFS) BY RECIST V.1.1.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
TNBC
28
100
II
Spain (and 4 other European countries)
Analysis
TRIAL OVERVIEW
PRESS RELEASE
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
TRIAL SITES
----
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi AntolÃn
Dr. Escrivá de RomanÃ
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page